Chemomab Therapeutics logo
Chemomab Therapeutics
CMMB | NASDAQ
Chart Builder DCF Calculator
$1.62
+$0.09 (+5.88%)
At close: Nov 16, 2026, 4:00 PM ET
$1.62
$0.00 (+0.15%)
After-hours: Nov 16, 2026, 5:32 PM ET

Chemomab Therapeutics Company Profile

Company profile explained

Company Profile

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

Key Executives

Name Position
Adi Mor George Co-Founder, Chief Scientific Officer, Chief Executive Officer & Executive Director
Sigal Fattal Chief Financial Officer
Barbara Lindheim Consulting Vice President of Investor & Public Relations, Strategic Communications
David Weiner Interim Chief Medical Officer
John Lawler Chief Development Officer

Latest SEC Filings

Date Type Title
Oct 30, 2026 DEFM14A Filing
Oct 29, 2026 S-4/A [Amend] Filing
Oct 19, 2026 6-K Filing
Oct 19, 2026 S-4/A [Amend] Filing
Sep 30, 2026 6-K Filing
Sep 25, 2026 S-4 Filing
Sep 09, 2026 SC 13D/A [Amend] Filing
Sep 01, 2026 4 Filing
Aug 19, 2026 6-K Filing
Aug 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Chemomab Therapeutics
Chemomab Therapeutics logo
Country Israel
IPO Date Feb 12, 2019
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Adi Mor George

Contact Details

Building C Tel Aviv-Yafo, TA 6158101 Israel

Stock Details

Ticker Symbol CMMB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534248
CUSIP Number 16385C203
ISIN Number US16385C2035
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.